UPDATED May 06, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$766.68 | 4.0% | 77.2% | US$690.3b | US$848.35 | PE112.5x | E27.0% | 0.7% | Pharmaceuticals & Biotech | ||
UNH | US$494.38 | 1.1% | 0.4% | US$454.9b | US$567.36 | PE29.6x | E19.6% | 1.5% | Healthcare | ||
JNJ | US$148.58 | 1.2% | -8.5% | US$357.6b | US$173.26 | PE20.9x | E7.0% | 3.3% | Pharmaceuticals & Biotech | ||
MRK | US$127.57 | -2.0% | 7.8% | US$323.1b | US$141.64 | PE140.1x | E24.9% | 2.4% | Pharmaceuticals & Biotech | ||
ABBV | US$162.73 | 0.7% | 10.4% | US$287.4b | US$182.31 | PE48.3x | E23.3% | 3.8% | Pharmaceuticals & Biotech | ||
AZN | UK£120.50 | 0.2% | 1.1% | UK£186.8b | UK£131.66 | PE37.1x | E16.5% | 2.0% | Pharmaceuticals & Biotech | ||
TMO | US$573.55 | -0.6% | 5.7% | US$218.9b | US$625.47 | PE36.3x | E10.6% | 0.3% | Pharmaceuticals & Biotech | ||
ABT | US$105.64 | -1.5% | -4.7% | US$183.8b | US$126.14 | PE32.8x | E11.3% | 2.1% | Healthcare | ||
DHR | US$247.40 | 0.2% | 3.4% | US$183.2b | US$272.68 | PE45x | E13.5% | 0.4% | Pharmaceuticals & Biotech | ||
AMGN | US$299.48 | 8.4% | 27.6% | US$160.7b | US$313.31 | PE42.7x | E17.8% | 3.0% | Pharmaceuticals & Biotech | ||
PFE | US$28.16 | 9.8% | -27.2% | US$159.5b | US$31.89 | PS2.9x | E29.7% | 6.0% | Pharmaceuticals & Biotech | ||
ISRG | US$383.05 | 2.4% | 26.4% | US$135.9b | US$420.38 | PE68.4x | E11.6% | n/a | Healthcare | ||
SYK | US$325.50 | -3.9% | 12.9% | US$124.0b | US$372.35 | PE36.9x | E10.5% | 1.0% | Healthcare | ||
ELV | US$529.93 | -0.8% | 13.9% | US$123.2b | US$603.15 | PE19.7x | E12.2% | 1.2% | Healthcare | ||
MDT | US$81.76 | 1.1% | -9.3% | US$108.6b | US$94.77 | PE25.8x | E9.7% | 3.4% | Healthcare | ||
BSX | US$72.55 | 0.07% | 36.6% | US$106.7b | US$81.17 | PE60.5x | E18.2% | n/a | Healthcare | ||
REGN | US$958.64 | 7.4% | 27.5% | US$105.6b | US$1,033.38 | PE27.4x | E12.2% | n/a | Pharmaceuticals & Biotech | ||
VRTX | US$402.50 | 1.6% | 17.0% | US$104.0b | US$460.23 | PE28.7x | E11.4% | n/a | Pharmaceuticals & Biotech | ||
CI | US$342.41 | -3.9% | 29.4% | US$97.3b | US$391.82 | PE26.9x | E18.0% | 1.6% | Healthcare | ||
BMY | US$43.90 | -1.7% | -35.8% | US$89.0b | US$53.19 | PS2x | E43.8% | 5.5% | Pharmaceuticals & Biotech | ||
GSK | UK£17.34 | 3.8% | 18.5% | UK£70.7b | UK£20.20 | PE15.8x | E11.9% | 3.3% | Pharmaceuticals & Biotech | ||
CSL | AU$275.50 | 0.2% | -8.6% | AU$133.1b | AU$306.40 | PE35.7x | E14.7% | 1.3% | Pharmaceuticals & Biotech | ||
GILD | US$65.54 | -0.6% | -16.6% | US$81.7b | US$83.43 | PE168.5x | E37.1% | 4.7% | Pharmaceuticals & Biotech | ||
HCA | US$310.06 | -0.4% | 11.6% | US$81.2b | US$344.35 | PE14.8x | E6.0% | 0.9% | Healthcare |